Massachusetts Financial Services Co. MA raised its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 519,701 shares of the company’s stock after purchasing an additional 13,547 shares during the quarter. Massachusetts Financial Services Co. MA owned 0.92% of Harmony Biosciences worth $15,679,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of HRMY. LSV Asset Management raised its position in Harmony Biosciences by 346.5% in the 1st quarter. LSV Asset Management now owns 335,146 shares of the company’s stock valued at $11,254,000 after buying an additional 260,093 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Harmony Biosciences by 53.7% in the second quarter. American Century Companies Inc. now owns 681,536 shares of the company’s stock valued at $20,562,000 after purchasing an additional 238,140 shares during the last quarter. Capital Management Corp VA bought a new stake in shares of Harmony Biosciences in the first quarter worth $7,018,000. Janus Henderson Group PLC boosted its holdings in Harmony Biosciences by 1,011.7% during the first quarter. Janus Henderson Group PLC now owns 185,083 shares of the company’s stock worth $6,214,000 after purchasing an additional 168,434 shares during the last quarter. Finally, Hedeker Wealth LLC bought a new position in Harmony Biosciences in the first quarter valued at $2,627,000. 86.23% of the stock is currently owned by institutional investors.
Harmony Biosciences Stock Performance
Shares of NASDAQ HRMY opened at $39.29 on Friday. Harmony Biosciences Holdings, Inc. has a 12 month low of $18.61 and a 12 month high of $39.73. The stock has a 50 day moving average of $35.22 and a 200-day moving average of $32.25. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $2.23 billion, a P/E ratio of 17.01, a P/E/G ratio of 0.75 and a beta of 0.73.
Wall Street Analyst Weigh In
Several equities research analysts have commented on HRMY shares. UBS Group started coverage on shares of Harmony Biosciences in a research report on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target on the stock. Citigroup started coverage on Harmony Biosciences in a research report on Friday, June 21st. They set a “buy” rating and a $48.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a research note on Thursday, September 12th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Harmony Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $41.33.
Get Our Latest Research Report on HRMY
Harmony Biosciences Company Profile
Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Further Reading
- Five stocks we like better than Harmony Biosciences
- Basic Materials Stocks Investing
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What is the Shanghai Stock Exchange Composite Index?
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Stock Dividend Cuts Happen Are You Ready?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report).
Receive News & Ratings for Harmony Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harmony Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.